skip to Main Content

Novel Agents Move the Needle Forward in Metastatic Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
While the use of combination chemotherapies has served to improve outcomes for patients with metastatic pancreatic cancer, new research examining novel agents like devimistat (formerly CPI-613) could continue to move the needle forward, according to Raymond Wadlow, MD.

“There is a lot of excitement surrounding some of these novel agents, a lot of work being done in improving the quality of patients’ lives, and a lot of work being done to find new ways to detect disease when it is still at an early stage or to prevent it,” Wadlow said. Read more . . . 


Back To Top